cannabis_print_logoCannabis Science, Inc. is a development-stage company involved in medical marijuana research and development. The company is committed to creating medicines—both with and without psychoactive properties—that are cannabis-based. These medicines aim to treat both the disease and its symptoms, and are also for general health maintenance. Cannabis Science, Inc. is the first and only publicly traded biotech company in the market that is involved in cannabinoid-based extracts, and trades in the OTC market under the symbol CBIS.

To put it simply, the company’s products are medical cannabinoid formulations that stem from at least one of the cannabinoid compounds of the cannabis plant with a primary focus of treating cancer—one of the most important diseases across the globe.

Formerly known as Gulf Onshore, Inc., Cannabis Science is among the oldest companies in the cannabis industry. From the very beginning, its founders have been dedicated to their cause of nurturing and upholding a spirit that encourages innovation from which novel ideas develop and turn into solutions based on evidence.

Thanks to its unique understanding of metabolic processes, the patent-oriented biotech company aims to provide alternative treatment options for individuals with medical needs that are unmet. The company utilizes an inquiring approach in order to discover and develop therapies that can improve patients’ lives.

Cannabis Science continues to create these products with medical cannabinoid formulations as part of its commitment to advocate for the rights of those dealing with life-threatening and debilitating conditions. It works closely with regulatory agencies on local, national, and international levels to ensure the accessibility of their high-quality cannabinoid pharmaceuticals.

Cannabis Science, Inc. works closely with leading experts in clinical research, drug development, and medicinal characterization to develop, create, and commercialize new therapeutic approaches that treat an extensive number of critical ailments such as infections, cancer, and age-related illnesses. All of the materials used in Cannabis Science’s clinical trial are from cultivation and production facilities that are GMP compliant, and that exceed industry standards and food processing requirements.


Yahoo! Finance: CBIS News

Latest Financial News for CBIS

Cannabis Science Set to Participate in the Premier Event Focused on High-Impact Global Collaborations; The Global Health Catalyst Summit at Harvard Medical School Starts Today

IRVINE, CA, May 24, 2019 -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to.

Cannabis Science Announces NFL Greats Past and Present Set to Participate and Partner With the Global Health Catalyst Summit at Harvard Medical School on May 24-26, 2019

IRVINE, CA, May 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the upcoming Global Health Catalyst (GHC) Summit at Harvard Medical School has been further enhanced with the announced participation of some of the greatest NFL Players of all time. The expectation by Summit organizers and participants is that this year’s event will be the biggest and most impactful GHC Summit to date. “For Cannabis Science, this is a dream come true!” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder.

Cannabis Science and Dana-Farber Cancer Institute Sign a New Research Agreement to Investigate Proprietary Extract From Justicia Plant

IRVINE, CA, May 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has entered into a new Research Collaboration Agreement with Dana-Farber Cancer Institute, Inc. to investigate the potential use of a proprietary extract from the Justicia plant to treat a number of blood disorders. There are a number of products that have been initially identified for development based on current research on the proprietary extract from the Justicia plant.

Cannabis Science Releases Clinical Drug-Development Pipeline as it Transitions Into Clinical Trials; Right on Time for the Upcoming Global Health Catalyst Summit at Harvard Medical School, May 24-26, 2019

IRVINE, CA, May 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, hits inflection point that translates into an unprecedented progression to clinical trials. With this change of atmosphere, the company is proud to release its 2019 Clinical Drug Development Pipeline and categorized industry sector inventory lists. The Summit is scheduled for May 24-26, 2019 in Boston, MA.

How Cannabis Growers are Keeping up with Incredible Demand

Corporate America is just beginning to invest in it, including retailers, alcohol companies, health, wellness and beauty. President Trump signed the Farm Bill into law. For example, Arcview Research and BDS Analytics forecast 38% global growth in 2019 to $16.9 billion.